48North Cannabis Corp. V.NRTH

Primary Symbol: NCNNF

Healthcare Drug Manufacturers - Specialty & Generic

48North Cannabis Corp is a vertically integrated cannabis company. It is focused on the health and wellness market through cultivation and extraction, as well as the creation of authentic brands for consumer-friendly products. Its products are categorized into Bath, Intimacy, Flower, Pre-roll, topical, vapes, concentrates, and accessories. It has two geographical segments: Canada, which is the key revenue driver; and the United States.

OTCPK:NCNNF - Post by User

48North Cannabis Corp. > When The Shorts Try To Scare You Into Selling

<< Previous

Bullboard Posts

Next >>

Post by ILIKETAon Oct 21, 2019 4:10pm

146 Views

Post# 30252491

When The Shorts Try To Scare You Into Selling

Remember this...
Under accounting rules, fair value adjustments for cannabis companies count newly produced marijuana/cannabis products as revenue (before it is even sold), minus production expenses.

Q1 (July Aug Sept) - reports at the end of Nov

So we should see a very large increase in revenues for this quarter because it should include:

- the autoflower harvest (estimated at about 1/10th of the outdoor harvest)
- sales from the OCS, the SQDC and the AGLC
- sales from Quill
- sales to Canopy Growth
- etc

Cannabis Summary for Oct. 15, 2019

2019-10-15 21:36 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The Canadian Securities Exchange Composite Index rose 12.52 points to 452.36 Tuesday, lifted by positive results from Aphria Inc. (APHA). Aphria jumped 96 cents to $7.17 on 13.3 million shares after reporting its second straight profitable quarter. The company earned $16.4-million in the fiscal first quarter (ended Aug. 31, 2019), up from earnings of $15.8-million in fiscal Q4. Aphria's $16.4-million profit from this quarter is largely the result of fair value adjustments. (Under accounting rules, fair value adjustments for cannabis companies count newly produced marijuana/cannabis products as revenue (before it is even sold), minus production expenses.) The company had a net gain of $17.8-million on these fair value adjustments in fiscal Q1.
Aphria's total revenue of $126.1-million in fiscal Q1 was slightly down from the $128.6-million that it recorded in the previous quarter, and below analyst expectations of $130.6-million. The decrease is the result of a small decline in revenue from Aphria's German distribution business, CC Pharma. That decline was partially offset by increased net revenue on cannabis sales, which reached $30.8-million in Q1, up from $28.6-million. It could have been a more significant increase, but Aphria lost an estimated $1.5-million of cannabis sales as a result of a fire at its Broken Coast facility on Vancouver Island. While Aphria's cannabis sales were up, so were its costs to produce that cannabis; Aphria spent $1.43 per gram in fiscal Q1, compared with $1.35 in the quarter before.

[url=https://www.stockwatch.com/News/Item.aspx?bid=Z-C:*MKTPOT-2819851&symbol=*MKTPOT®ion=C]https://www.stockwatch.com/News/Item.aspx?bid=Z-C:*MKTPOT-2819851&symbol=*MKTPOT®ion=C[/url]